21 research outputs found

    Teaching computing for complex problems in civil engineering and geosciences using big data and machine learning: synergizing four different computing paradigms and four different management domains

    No full text
    Abstract This article describes a teaching strategy that synergizes computing and management, aimed at the running of complex projects in industry and academia, in the areas of civil engineering, physics, geosciences, and a number of other related fields. The course derived from this strategy includes four parts: (a) Computing with a selected set of modern paradigmsā€”the stress is on Control Flow and Data Flow computing paradigms, but paradigms conditionally referred to as Energy Flow and Diffusion Flow are also covered; (b) Project management that is holisticā€”the stress is on the wide plethora of issues spanning from the preparation of project proposals, all the way to incorporation activities to follow after the completion of a successful project; (c) Examples from past research and development experiencesā€”the stress is on experiences of leading experts from academia and industry; (d) Student projects that stimulate creativityā€”the stress is on methods that educators could use to induce and accelerate the creativity of students in general. Finally, the article ends with selected pearls of wisdom that could be treated as suggestions for further elaboration

    Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

    No full text
    Background: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. Methods: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ā‰„18 years) with biopsy-proven IgA nephropathy and proteinuria of 1Ā·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to 1Ā·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. Findings: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49Ā·8%) than the irbesartan group (-15Ā·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0Ā·59; 95% CI 0Ā·51-0Ā·69; p<0Ā·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. Interpretation: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. Funding: Travere Therapeutics

    Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

    No full text
    Background Sparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary endpoint) in patients with immunoglobulin A nephropathy in the phase 3 PROTECT trial's previously reported interim analysis. Here, we report kidney function and outcomes over 110 weeks from the double-blind final analysis. Methods PROTECT, a double-blind, randomised, active-controlled, phase 3 study, was done across 134 clinical practice sites in 18 countries throughout the Americas, Asia, and Europe. Patients aged 18 years or older with biopsy-proven primary IgA nephropathy and proteinuria of at least 1Ā·0 g per day despite maximised reninā€“angiotensin system inhibition for at least 12 weeks were randomly assigned (1:1) to receive sparsentan (target dose 400 mg oral sparsentan once daily) or irbesartan (target dose 300 mg oral irbesartan once daily) based on a permuted-block randomisation method. The primary endpoint was proteinuria change between treatment groups at 36 weeks. Secondary endpoints included rate of change (slope) of the estimated glomerular filtration rate (eGFR), changes in proteinuria, a composite of kidney failure (confirmed 40% eGFR reduction, end-stage kidney disease, or all-cause mortality), and safety and tolerability up to 110 weeks from randomisation. Secondary efficacy outcomes were assessed in the full analysis set and safety was assessed in the safety set, both of which were defined as all patients who were randomly assigned and received at least one dose of randomly assigned study drug. This trial is registered with ClinicalTrials.gov, NCT03762850. Findings Between Dec 20, 2018, and May 26, 2021, 203 patients were randomly assigned to the sparsentan group and 203 to the irbesartan group. One patient from each group did not receive the study drug and was excluded from the efficacy and safety analyses (282 [70%] of 404 included patients were male and 272 [67%] were White) . Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6ā€“110) was āˆ’2Ā·7 mL/min per 1Ā·73 m2 per year versus āˆ’3Ā·8 mL/min per 1Ā·73 m2 per year (difference 1Ā·1 mL/min per 1Ā·73 m2 per year, 95% CI 0Ā·1 to 2Ā·1; p=0Ā·037); total 2-year slope (day 1ā€“week 110) was āˆ’2Ā·9 mL/min per 1Ā·73 m2 per year versus āˆ’3Ā·9 mL/min per 1Ā·73 m2 per year (difference 1Ā·0 mL/min per 1Ā·73 m2 per year, 95% CI āˆ’0Ā·03 to 1Ā·94; p=0Ā·058). The significant reduction in proteinuria at 36 weeks with sparsentan was maintained throughout the study period; at 110 weeks, proteinuria, as determined by the change from baseline in urine protein-to-creatinine ratio, was 40% lower in the sparsentan group than in the irbesartan group (āˆ’42Ā·8%, 95% CI āˆ’49Ā·8 to āˆ’35Ā·0, with sparsentan versus āˆ’4Ā·4%, āˆ’15Ā·8 to 8Ā·7, with irbesartan; geometric least-squares mean ratio 0Ā·60, 95% CI 0Ā·50 to 0Ā·72). The composite kidney failure endpoint was reached by 18 (9%) of 202 patients in the sparsentan group versus 26 (13%) of 202 patients in the irbesartan group (relative risk 0Ā·7, 95% CI 0Ā·4 to 1Ā·2). Treatment-emergent adverse events were well balanced between sparsentan and irbesartan, with no new safety signals. Interpretation Over 110 weeks, treatment with sparsentan versus maximally titrated irbesartan in patients with IgA nephropathy resulted in significant reductions in proteinuria and preservation of kidney function.</p

    Modelling and Evaluating Capability of Battery Storage Systems to Provide Extreme Event Services to the DSO: Case Study of Croatia

    No full text
    peer reviewedThe City of Zagreb in Croatia and its surroundings have experienced two strong earthquakes within nine months of 2020. Putting this in the context of the increased workload of healthcare facilities due to Covid-19, the distribution system operator (DSO) is encouraged to look for unconventional solutions such as integrating the battery energy storage system (BESS) to supply healthcare facilities during network fault conditions or other extreme network events. The BESS size and location are determined by optimization model, while the control system of the BESS converter, based on the virtual synchronous machine (VSM) concept, is define to test BESS ability to supply critical consumers in the off-grid mode. The models are tested and verified on several real world situations in Zagreb MV distribution network. Future developments and scenarios are also simulated to verify the robustness of the proposed investment.9. Industry, innovation and infrastructur

    Psihometrijska validacija intervjua za kliničku procjenu negativnih sindroma (CAINS) na uzorku osoba sa psihotičnim poremećajima u Crnoj Gori

    No full text
    Glavni cilj provedene studije bio je ispitivanje pouzdanosti i konstruktne valjanosti Intervjua za kliničku procjenu negativnih simptoma (CAINS). Uzorak su činile osobe sa dijagnozom nekog od psihotičnih poremećaja. Dva istraživača procijenila su 122 ispitanika (67 žena i 55 muÅ”karaca) u četiri sljedeće zdravstvene institucije u Crnoj Gori: Klinika za psihijatriju Kliničkog Centra Crne Gore, Specijalna bolnica za psihijatriju ā€œDobrotaā€ i Dom zdravlja u Kotoru, kao i Dom zdravlja ā€œNika Labovićā€, Berane. Rezultati ukazuju na očekivanu dvodimenzionalnu latentnu strukturu CAINS-a, pri čemu ajtemi odgovaraju pretpostavljenim dimenzijama (Motivaciji i zadovoljstvu, kao i Ekspresiji). Dvodimenzionalno rjeÅ”enje obuhvatilo je 55.20% varijanse ajtema. Pouzdanost Motivacije i zadovoljstva iznosila je Ī± = .827, a Ekspresije Ī± = .922. Dimenzija Motivacija i zadovoljstvo bila je u niskoj, a Ekspresija u umjerenoj do visokoj pozitivnoj korelaciji sa zaravnjenim afektom, emocionalnim povlačenjem i motornom retardacijom (mjerenih Kratkom skalom psihijatrijske procjene - BPRS). Rezultati su prodiskutovani u kontekstu prethodnih istraživanja i specifičnosti psihopatologije osoba oboljelih od psihičkih poremećaj

    Psihometrijska validacija intervjua za kliničku procjenu negativnih sindroma (CAINS) na uzorku osoba sa psihotičnim poremećajima u Crnoj Gori

    No full text
    Glavni cilj provedene studije bio je ispitivanje pouzdanosti i konstruktne valjanosti Intervjua za kliničku procjenu negativnih simptoma (CAINS). Uzorak su činile osobe sa dijagnozom nekog od psihotičnih poremećaja. Dva istraživača procijenila su 122 ispitanika (67 žena i 55 muÅ”karaca) u četiri sljedeće zdravstvene institucije u Crnoj Gori: Klinika za psihijatriju Kliničkog Centra Crne Gore, Specijalna bolnica za psihijatriju ā€œDobrotaā€ i Dom zdravlja u Kotoru, kao i Dom zdravlja ā€œNika Labovićā€, Berane. Rezultati ukazuju na očekivanu dvodimenzionalnu latentnu strukturu CAINS-a, pri čemu ajtemi odgovaraju pretpostavljenim dimenzijama (Motivaciji i zadovoljstvu, kao i Ekspresiji). Dvodimenzionalno rjeÅ”enje obuhvatilo je 55.20% varijanse ajtema. Pouzdanost Motivacije i zadovoljstva iznosila je Ī± = .827, a Ekspresije Ī± = .922. Dimenzija Motivacija i zadovoljstvo bila je u niskoj, a Ekspresija u umjerenoj do visokoj pozitivnoj korelaciji sa zaravnjenim afektom, emocionalnim povlačenjem i motornom retardacijom (mjerenih Kratkom skalom psihijatrijske procjene - BPRS). Rezultati su prodiskutovani u kontekstu prethodnih istraživanja i specifičnosti psihopatologije osoba oboljelih od psihičkih poremećaj

    Izrada računalne 2D video igre koriŔtenjem Unreal razvojnog okruženja

    Get PDF
    Diplomski rad će obuhvaćati proces izrade i razvoja platformske video igre pomoću razvojnog okruženja Unreal Engine. Postupci razvoja igre od ideje do finalnog proizvoda će biti detaljno dokumentirani. Ideja rada je spoj grafičke struke s razvojem video igara, odnosno prikazati primjenu grafičke struke i važnost koju ima unutar razvoja video igara. Cilj je postizanje vizualnog rjeÅ”enja računalne igre i svih njenih popratnih vizualnih elemenata zajedno s programskim kodom te kreiranje samostalne fluidne i funkcionalne cjeline. Daljnjom razradom će se objasniti proces potreban za projektiranje i razvoj video igre te znanja, vjeÅ”tine i tehnologije potrebne za realizaciju projekta. Takav proces zahtjeva pomno planiranje i jasne ciljeve koji će biti detaljno dokumentirani i prikazani pomoću slikovnih i shematskih objaÅ”njenja. Svaki postupak u procesu razvoja igre će biti dokumentiran pojedinačno tijekom ovoga rada. Ovim se projektom 2D platformera želi prikazati sve veći utjecaj grafičkog dizajna unutar industrije razvoja video igara i na sami razvoj i poboljÅ”anje vizualnog identiteta i vizualnih elemenata samih video igara te se želi realizirati jedna zabavna cjelina sastavljena od grafičkih elemenata i programskog koda, kojima se želi prikazati sva kompleksnost i povezanost programerskih, razvojnih i grafičkih struka unutar razvoja video igara. Projekt je cjelokupno vlastito rjeÅ”enje u kojem autor koristi vlastoručno izrađene vizualne elemente i animacije koje su esencijalne za uspjeh video igre

    AgrobioloŔka i tehnoloŔka svojstva sorte Frankovka u uslovima severne Kosovske Mitrovice

    Get PDF
    Results of the investigation of agrobiological traits and technological properties of the vine cultivar Frankovka are presented in this paper. The investigation was carried out in North Kosovska Mitrovica, nearby the Church of St. Dimitrios. The vineyard was established in 2005. Planting distance was 2.5 x1m. Weather conditions were favorable for development of the cultivar Frankovka. The study was aimed to observe important agrobiological traits of the cultivar Frankovka, as well as possibility growing and spreading in the conditions of North Kosovska Mitrovica. On the basis of the obtained results it can be concluded that the cultivar Frankovka has shown positive agrobiological and technological properties in the conditions of North Kosovska Mitrovica.U radu se prikazuju rezultati istraživanja agrobioloÅ”kih i tehnoloÅ”kih svojstava sorte frankovka u uslovima severne Kosovske Mitrovice.Ispitivanja su obavljena na potesu vinogradi u severnoj Kosovskoj Mitrovici.Vinograd je podignut 2005. godine i nalazi se u fazi rastuće rodnosti.Razmak sađenja iznosi 2.5 x 1 m .U periodu ispitivanja vladali su povoljni meteoroloÅ”ki uslovi za rastenje i razviće sorte frankovke. Cilj ispitivanja je bio da se provere važnija agrobioloÅ”ka i tehnoloÅ”ka svojstva sorte frankovke i mogućnost njenog gajenja i Å”irenja u uslovima severne Kosovske Mitrovice. Rezultati ispitivanja ukazuju da na području severne Kosovske Mitrovice postoje povoljni agroekoloÅ”ki uslovi za normalno gajenje sorte frankovke i postizanje karakterističnog kvaliteta grožđa i vina

    Cbl-ArgBP2 complex mediates ubiquitination and degradation of c-Abl.

    No full text
    The mechanisms leading to the ubiquitination and degradation of the activated c-Abl kinase have not yet been identified. We found that the multi-adaptor protein ArgBP2 links c-Abl to the ubiquitin ligase Cbl. Phosphorylation of Cbl and ArgBP2 by c-Abl resulted in the stabilization of their interactions, thus facilitating Cbl-induced ubiquitination and subsequent degradation of c-Abl and ArgBP2
    corecore